Hereditary Angioedema

Business

Analysts Boost Targets for KalVista Ahead of Key Q4 Report, Citing Oral HAE Therapy Potential

TD Cowen and H.C. Wainwright have raised price targets on KalVista Pharmaceuticals, expressing confidence in its oral hereditary angioedema treatment ahead of the company's fourth-quarter financial results.

Business

Intellia Therapeutics Sees Analyst Price Target Surge After FDA Lifts Clinical Hold on Key Gene Therapy Trial

Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.